Over Two-Thirds of Cervical Cancer Deaths Prevented
News Sep 19, 2016
The new research, funded by Cancer Research UK and published in the British Journal of Cancer, is the first to establish the impact that screening has on deaths from cervical cancer by using screening information from women who have been diagnosed with the disease.
The researchers studied the records of more than 11,000 women in England who had been diagnosed with cervical cancer and found that, without screening, an additional 1,827 more women would die from the disease. But if all women aged between 25 and 64 were screened regularly, an extra 347 lives could be saved – extensively reducing the number of deaths from the disease.
The biggest impact of screening is among women aged between 50-64 where there would be five times more women dying from cervical cancer if there were no screening.
Lead researcher Professor Peter Sasieni from QMUL’s Wolfson Institute of Preventive Medicine said: “This study looked at the impact of cervical screening on deaths from the disease and estimated the number of lives the screening programme saves each year.
“Thousands of women in the UK are alive and healthy today thanks to cervical screening. The cervical screening programme already prevents thousands of cancers each year and as it continues to improve, by testing all samples for the human papilloma virus, even more women are likely to avoid this disease.”
In England around 800 women die from cervical cancer each year. Cervical cancer screening is offered in the UK to women aged between 25 and 64. The screening programme invites women every three years between the 25 and 49; after that they are invited every five years until they’re 64.
Dr Claire Knight, health information manager at Cancer Research UK, said: “Whether or not to go for screening is an individual choice, but Cancer Research UK recommends women take up the offer to attend cervical screening when invited.
“It’s important to remember that cervical screening is for women without symptoms. Women who have any unusual or persistent bleeding, pain, or change in vaginal discharge - even if they’ve been screened recently and whatever their age - should get it checked out by their GP. Chances are it won’t be cancer but, if it is, getting it diagnosed and treated early can make a real difference.”
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE